These therapeutic agents inhibit VEGF from binding to its receptors (VEGFR-1 and VEGFR-2), thereby suppressing tumor angiogenesis, improving the tumor microenvironment, and enhancing chemotherapy drug delivery efficiency. This evidence concerns the gene FLT1 and neoplasm.